228
Views
2
CrossRef citations to date
0
Altmetric
The Economics of Business: Perspectives on Research

Two Paradoxes in the Theory of Capital Investment and Competition

References

  • Barzel, Yoram. 1968. Optimal Timing of Innovations. Review of Economics and Statistics 50 (3): 348–355.
  • Comanor, William S., and F. M. Scherer. 2013. Mergers and Innovation in the Pharmaceutical Industry. Journal of Health Economics 32 (1): 106–113.
  • Dean, Joel. 1951. Capital Budgeting. New York: Columbia University Press.
  • Hall, Bronwyn, Jacques Mairesse, and Pierre Mohnen. 2010. Measuring the Returns to R&D. In Handbook on the Economics of Innovation, edited by Bronwyn Hall and Nathan Rosenberg, 1033–1082. Amsterdam: North-Holland.
  • Hirshleifer, Jack. 1970. Investment, Interest, and Capital. Englewood Cliffs, NJ: Prentice-Hall.
  • Keynes, John Maynard. 1936. The General Theory of Employment Interest and Money. New York: Harcourt Brace.
  • Scherer, F. M. 1967. Research and Development Resource Allocation under Rivalry. Quarterly Journal of Economics 81 (3): 359–394.
  • Scherer, F. M. 1982. Interindustry Technology Flows and Productivity Growth. Review of Economics and Statistics 64 (4): 627–634.
  • Scherer, F. M. 1996. Industry Structure, Strategy, and Public Policy. New York: Harper-Collins.
  • Scherer, F. M. 2001. The Link between Gross Profitability and Pharmaceutical R&D Spending. Health Affairs 20 (5): 216–220.
  • Scherer, F. M. 2010. Pharmaceutical Innovation. In Handbook on the Economics of Innovation, edited by Bronwyn Hall and Nathan Rosenberg, 539–574, 539–574. Amsterdam: North Holland.
  • Scherer, F. M., and David Ross. 1990. Industrial Market Structure and Economic Performance. 3rd ed. Boston: Houghton-Mifflin.
  • Schmalensee, Richard. 1989. Inter-Industry Studies of Structure and Performance. In Handbook of Industrial Organization, edited by Richard Schmalensee and Robert Willig, 951–1009. Amsterdam: North-Holland.
  • Stauffer, Thomas. 1971. The Measurement of Corporate Rates of Return: A Generalized Formulation. Bell Journal of Economics and Management Science 2 (2): 434–469.
  • U.S. Office of Technology Assessment. 1993. Pharmaceutical R&D: Costs, Risks, and Rewards. Washington, DC: Government Printing.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.